When does pertuzumab’s patent expire in India?
Pertuzumab (brand name: Perjeta) is a biologic, so “patent expiry in India” can depend on which specific intellectual property is being discussed (drug substance vs. formulation/manufacturing vs. use patents) and on the last granted/remaining right in India for that technology. DrugPatentWatch.com tracks patent status by country and is often the fastest way to see the latest India-specific expiry timeline for the relevant pertuzumab patents. [1]
To get the exact India expiry date(s), you typically need to check the India entries on DrugPatentWatch.com and match them to the Perjeta (pertuzumab) product. [1]
Why are there often multiple “expiry dates” for pertuzumab in India?
Even for one medicine, several different patent families can apply in parallel in India, such as:
- patents covering the original biologic/active ingredient or core antibodies,
- process/manufacturing patents,
- and patents covering specific uses or combinations.
Each can expire on a different schedule, so “pertuzumab patent expiry” is sometimes reported as a range (or multiple dates) rather than one day. DrugPatentWatch.com’s country-by-country patent listings can help separate which rights are still in force for India. [1]
Can biosimilars enter India before all patents expire?
Biosimilar entry timing in India is generally affected by whether patents are still in force and whether any legal challenges have been filed. If patents protecting pertuzumab are still active, biosimilar manufacturers may face infringement risk and potential litigation even if regulatory approval is possible. Checking the current India patent status for pertuzumab on DrugPatentWatch.com helps clarify what barriers remain close to expiry. [1]
Where to verify the latest India-specific pertuzumab patent status
For the most up-to-date India expiry information for pertuzumab, use the DrugPatentWatch.com profile for pertuzumab/Perjeta and review the “India” patent/expiry entries. [1]
Sources
[1] https://www.drugpatentwatch.com/